Talazoparib

Talazoparib, is an orally available poly-ADP-ribose polymerase (PARP) inhibitor which has been developed by Pfizer for the treatment of advanced breast cancer with germline BRCA mutations.

Highlights

In the year 2018, this drug was approved in the US and in the year 2019 it received approval to be used in the European Union. It received approval for locally advanced breast cancer or metastatic with germline BRCA mutation, HER2 negative.

Talazoparib acts as an inhibitor of poly-ADP-ribose polymerase (PARP), which aids in single-stranded DNA repair. Cells with BRCA1 / 2 mutations are susceptible to the cytotoxic effects of PARP inhibitors due to the accumulation of DNA damage. Talazoparib is believed to be more effective than olaparib due to the entrapment of PARP. PARP entrapment is the mechanism of action by which the PARP molecule becomes entrapped in DNA, affecting the replication capacity of cells.

Development of Talazoparib

BioMarin Pharmaceutical Inc. originally developed Talazoparib. Later, Medivation Inc. acquired it for $ 410 million with additional payments of up to $ 160 million in royalties. They acquired all worldwide rights of talazoparib in the year 2015 to expand its global oncology franchise.  Under this agreement, Medivation assumed full financial responsibility for the regulation, commercialization, development and regulation of talazoparib.

Side effects of using Talazoparib

The most serious side effects involve the hematopoietic system included neutropenia (low neutrophil count), anemia (low red blood cell count) and thrombocytopenia (low platelet count).

Severe forms of these diseases occurred in 21%, 39%, and 15% of patients. Other side effects include nausea, headache, fatigue and hair loss and they were mostly mild.

Related
Insulock	[Video] Current Affairs Today [#941] – Current Affairs – May 19, 2021 | Current Affairs by GKToday
Blackbuck	National Road Safety Board
Snow Leopard	MIS-C